A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

被引：0
|
作者：
Gericke, Germo [1 ]
机构：
[1] Novartis Co, Adv Accelerator Applicat, CH-1204 Geneva, Switzerland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / 09期
关键词：
1;
D O I：
10.1007/s00259-021-05400-5
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：2666 / 2667
页数：2
相关论文
共 50 条
  • [21] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
    Abuqbeitah, Mohammad
    Demir, Mustafa
    Uslu-Besli, Lebriz
    Yeyin, Nami
    Sonmezoglu, Kerim
    RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2018, 57 (01) : 55 - 61
  • [22] In Vivo Testing of 177Lu-Labelled Anti-PSMA Antibody as a New Radioimmunotherapeutic Agent Against Prostate Cancer
    Behe, Martin
    Alt, Karen
    Deininger, Friederike
    Buehler, Patrick
    Wetterauer, Ulrich
    Weber, Wolfgang A.
    Elsaesser-Beile, Ursula
    Wolf, Philipp
    IN VIVO, 2011, 25 (01): : 55 - 59
  • [23] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
    Mohammad Abuqbeitah
    Mustafa Demir
    Lebriz Uslu-Beşli
    Nami Yeyin
    Kerim Sönmezoğlu
    Radiation and Environmental Biophysics, 2018, 57 : 55 - 61
  • [24] Comparison of Red Marrow Dosimetry Methodologies for Lu-177-PSMA Radionuclide Therapy
    Lehnert, W.
    Apostolova, I.
    Buchert, R.
    Klutmann, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S76 - S77
  • [25] New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177)
    Zha, Zhihao
    Choi, Seok Rye
    Li, Linlin
    Zhao, Ruiyue
    Ploessl, Karl
    Yao, Xinyue
    Alexoff, David
    Zhu, Lin
    Kung, Hank F.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (19) : 13001 - 13012
  • [26] Development and preclinical evaluation of biodistribution and dosimetry of 177Lu-labelled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer
    Orlova, A.
    Abouzayed, A.
    Seitova, K.
    Lundmark, F.
    Bodenko, V.
    Oroujeni, M.
    Tolmachev, V.
    Rosenstrom, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S335 - S335
  • [27] Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
    Abdlkadir, Ahmed Saad
    Abufara, Alaa
    Al-Ibraheem, Akram
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 58 (06) : 381 - 382
  • [28] Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid
    Simsek, Duygu Has
    Kuyumcu, Serkan
    Agaoglu, Fulya Yaman
    Unal, Seher Nilgun
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 764 - 766
  • [29] Simplified Organ and Tumor Dosimetry for Lu-177-PSMA-I&T Radionuclide Therapy
    Lehnert, W.
    Schatz, L.
    Karimzadeh, A.
    Apostolova, I.
    Buchert, R.
    Klutmann, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S745 - S746
  • [30] Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during 177Lu-based radionuclide therapy: a study for 177Lu-DOTATATE and 177Lu-PSMA
    Gosewisch, A.
    Ermoschkin, L.
    Ilhan, H.
    Todica, A.
    Vamacka, L.
    Bartenstein, P.
    Boening, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S270 - S271
12345